Business and Finance

The company will participate in the Trump administration’s direct-to-patient drug platform, while committing $100 billion to US R&D and manufacturing.

The pharma giant will invest in a 35,000-square-foot RLT manufacturing site in Winter Park, FL as part of its $23 billion US infrastructure expansion.

Novo Nordisk’s newly approved oral semaglutide is now available nationwide through Amazon Pharmacy with insurance and cash-pay options.

In today’s Pharma Pulse, Johnson & Johnson secures a major tariff deal by joining the federal drug discount portal, while new data warns that missing early infant shots is the leading predictor of skipped MMR vaccines.

The pharma giant becomes the latest manufacturer to participate in the Trump Administration’s direct-to-patient pricing platform, aligning US drug costs with European benchmarks while reinforcing its domestic manufacturing investments.

In today’s Pharma Pulse, healthcare leaders brace for a surge in dealmaking, Eli Lilly secures a suite of oral NLRP3 inhibitors, and Knipper Health rebrands to streamline the path from order to therapy.

Backed by Frazier Healthcare Partners and strengthened by the acquisition of eBlu Solutions, CareTria aims to accelerate patient access by combining provider technology, digital enrollment, and multi-modal fulfillment into a single end-to-end platform.

In today’s Pharma Pulse, the FDA issues two high-stakes priority vouchers for cholesterol and cancer therapies, GSK leverages genomic data to refine drug targets, and DHL completes a one-million-square-foot logistics center of excellence.

A new Foreign Trade Zone–enabled facility in Annville strengthens the company’s temperature-controlled, compliant logistics capabilities, while accelerating customs processing and last-mile healthcare delivery.

In today’s Pharma Pulse, federal officials slash the childhood immunization schedule, new data underscores the life-saving impact of COVID vaccines for COPD patients, and Eli Lilly targets the AMPK pathway in a massive new oral obesity collaboration.

In today’s Pharma Pulse, GoodRx slashes cash prices for the new Wegovy pill, a federal judge halts the 340B rebate pilot, and Sanofi doubles down on Earendil Labs’ AI platform for autoimmune breakthroughs.

The healthcare pricing platform is expanding access to Novo Nordisk’s newly approved oral GLP-1 for weight management, pairing transparent cash pricing with telehealth support nationwide.

In today’s Pharma Pulse, the FDA clears new denosumab biosimilars for osteoporosis and cancer-related bone loss, while healthcare leaders grapple with a surge in "nuclear verdicts" driven by shifting public sentiment.

In the first part of her Pharma Commerce video interview, Tina Martinez, vice president and head of global products and solutions at Cencora, describes how the company uses deep customer relationships and cross-enterprise collaboration to develop new products and solutions that address evolving market dynamics, improve efficiency, and support healthier outcomes.

The acquisition strengthens Yusen Logistics’ healthcare footprint across Europe, adding specialized transportation, warehousing, digital, and GDP-compliant capabilities to its regional and global network.

In today’s Pharma Pulse, Samsung Biologics enters the US market with a $280 million site acquisition, AstraZeneca secures a multi-billion-dollar cancer deal, and new research identifies occupational drivers of long COVID.

The South Korea–based CDMO acquires its first US manufacturing facility in Rockville, MD, expanding its global footprint and strengthening biologics capacity.

Bill Roth, general manager and managing partner of IntegriChain’s consulting business, previews his new six-part series by outlining how rising payer fragmentation, divergent cash and insurance models, and supply-chain constraints are reshaping brand strategy.

The acquisition strengthens CEVA’s global project logistics footprint, adding heavy-lift expertise, specialized engineering talent, and integrated solutions across key regions.

In today’s Pharma Pulse, Novartis and Moderna anchor a domestic manufacturing surge, while AI-driven biomarker discovery and physician well-being reshape the future of clinical care.

The pharmaceutical giant’s new 700,000-square-foot hub aims to onshore production of key medicines and strengthen the US drug supply chain.

In today’s Pharma Pulse, SOBI strengthens its gout franchise by acquiring Arthrosi Therapeutics for up to $1.5 billion, securing the Phase III asset pozdeutinurad, and much more.

A session explores how manufacturers can refine GTN strategy, strengthen pricing governance, and navigate increasingly complex distribution-channel economics, while maintaining both commercial performance and patient affordability.

BioCare's Ryan Cort outlines the pharmaceutical industry's "unprecedented sea change," driven by over $400 billion in anticipated revenue loss from generics and biosimilars losing exclusivity.

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and let’s get into today’s headlines.